Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) EBITDA (2016 - 2025)

Macrogenics (MGNX) has disclosed EBITDA for 14 consecutive years, with -$14.1 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 8.44% to -$14.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$74.6 million, a 11.4% decrease, with the full-year FY2025 number at -$74.6 million, down 11.4% from a year prior.
  • EBITDA was -$14.1 million for Q4 2025 at Macrogenics, down from $16.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $57.4 million in Q2 2023 to a low of -$66.7 million in Q1 2022.
  • A 5-year average of -$23.6 million and a median of -$39.0 million in 2021 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 2670.99% in 2021, then skyrocketed 238.8% in 2023.
  • Macrogenics' EBITDA stood at -$58.1 million in 2021, then skyrocketed by 122.23% to $12.9 million in 2022, then plummeted by 456.65% to -$46.0 million in 2023, then surged by 66.49% to -$15.4 million in 2024, then rose by 8.44% to -$14.1 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's EBITDA are -$14.1 million (Q4 2025), $16.8 million (Q3 2025), and -$36.3 million (Q2 2025).